Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company that develops groundbreaking cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, is pleased to announce the appointment of Paul Auwaerter, M.D. to its esteemed Board of Directors. With over 30 years of experience in internal medicine and infectious diseases, Dr. Auwaerter brings a wealth of expertise and knowledge to the Capricor team.
Capricor’s CEO, Linda Marbán, Ph.D. is thrilled to welcome Dr. Auwaerter to its Board of Directors. Dr. Auwaerter brings an over three decades of medical expertise and drug development experience to the team and will be a great asset in advancing the company’s therapeutic product candidates. His remarkable career has seen him work with some of the most prominent innovators in the life sciences industry, and his forward-thinking vision and experience make him an excellent addition to the team.
Dr. Auwaerter is delighted to join Capricor at a vital stage of its development. As an innovator with their late-stage CAP-1002 cell therapy program for Duchenne muscular dystrophy and its breakthrough exosomes platform – already demonstrating potential in early development – the Company presents an irresistible opportunity. He and the executive team, together with his fellow Board members, are keen to further progress Capricor’s exciting therapeutic pipeline.
Dr. Robert Auwaerter is a distinguished name in the medical field, serving multiple roles at the prestigious Johns Hopkins University School of Medicine. As Clinical Director of the Division of Infectious Diseases, Director of the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Chief Medical Officer for the Point of Care-Information Technology Center (POC-IT), and attending physician for medicine and pediatrics at Johns Hopkins Hospital and Clinics, Dr. Auwaerter is the driving force behind some of the most innovative research in modern healthcare. His credentials include an A.B. in Biology and M.D. in Medicine from Columbia University, as well as an M.B.A. from the Johns Hopkins University School of Professional Studies in Business and Education.
With over one hundred pieces of original research published to date, Dr. Auwaerter has established himself as the Sherrilyn and Ken Fisher Professor of Medicine in the Divisions of Infectious Diseases and General Internal Medicine at Johns Hopkins University School of Medicine, a post he has held since 1988.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is an innovative biotechnology company blazing a trail to develop cell and exosome-based life-changing therapeutics. Their leading therapy, CAP-1002, is a groundbreaking allogeneic cardiac-derived cell therapy being tested as a potential treatment for Duchenne muscular dystrophy.
Capricor also works to revolutionize its exosome technology, using exosomes to deliver proteins and nucleic acids to treat and prevent a variety of diseases. Recently, Nippon Shinyaku Co., Ltd. granted Capricor an exclusive commercialization and distribution agreement for CAP-1002 in the United States and Japan. The future looks bright for Capricor’s cutting-edge therapeutic products.